ev3 — Q2 2008 Earnings Presentation
13 slides from ev3's earnings presentation, Jul 28, 2008
Slide 1: Second Quarter of 2008 Highlights
Second Quarter of 2008 Highlights July 28, 2008
Slide 2: Forward-Looking Statements
3 Forward-Looking Statements Statements contained in this presentation that are not historical information are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and ope
Slide 3: Use of Non-GAAP Financial Measures
5 Use of Non-GAAP Financial Measures In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), ev3 uses certain non-GAAP financial measures. In this presentation, ev3 uses the non-GAAP financial measures, "EBITDA, excluding charges for non-cash st
Slide 4: Q2 Significant Financial Achievements
7 Q2 Significant Financial Achievements 7 Net sales of $107.7 million exceeded the high end of our guidance range of $101 to $103 million Legacy ev3 net sales, excluding Fox Hollow and research collaboration revenues, increased +17% vs. Q2 2007 Peripheral stents up +22%, the second sequential quarte
Slide 5: Actual Results vs. Last Quarter & Year Ago
Actual Results vs. Last Quarter & Year Ago 9 Q1 2008 Actual Q2 2007 Actual $000's except EPS Net Sales Gross Profit Gross Margin Net Loss EBITDA EBITDA, as adjusted GAAP EPS (loss) $65,396 $43,034 65.8% $(11,871) $(6,166) $(3,506) $(0.20) $101,257 $67,639 66.8% $(9,770) $1,450 $6,181 $(0.09) Q2 2008
Slide 6: Revenue Growth
Revenue Growth Q3 Q4 Q1 Q2 Q2 East 65.1 92.2 101.3 65.4 107.7 Total Worldwide ev3 ($M) +65% Q3 Q4 Q1 Q2 Q2 East 26.8 28 34.8 25.8 35.9 Total International ($M) +39% Q3 Q4 Q1 Q2 Q2 East 38.7 57.9 64.1 40.6 70.8 (a) Excludes FoxHollow revenue Worldwide Peripheral Vascular ($M) +74% Q3 Q4 Q1 Q2 Q2 East
Slide 7: Balance Sheet Highlights
13 Balance Sheet Highlights Q2 2007 Q3 2007 Q4 2007 Q1 2008 Q2 2008 Cash, Cash Equivalents & Short Term Investments $65,719 $57,136 $90,804 $57,000 $38,749 Total Debt $11,441 $10,892 $10,000 $9,107 $8,214 Working Capital $128,872 $96,950 $109,211 $107,791 $103,284 Stockholders' Equity $336,586 $303,
Slide 8: Q2 Operational Highlights
15 Q2 Operational Highlights 15 Emphasis on improved productivity within U.S. peripheral vascular sales force showing positive sequential quarterly progress*: Q208: ~$1.5 million per territory Q108: ~$1.4 million per territory Q407: ~$1.3 million per territory Completed co-marketing agreement with B
Slide 9: Guidance as of July 28, 2008
17 Guidance as of July 28, 2008 Revenues: Q3 2008: $104 to $106 million1 Full-Year 2008: $425 to $430 million2 Adjusted EPS (loss)3 per diluted share: Q3 2008: $(0.02) to $0.013,4 Full-Year 2008: $0.00 to $0.053,4 Consists of $100 to $102 million of product net sales and $4.1 million of research col
Slide 10: Business Model Structure
Business Model Structure 2008 Goal % of sales Sales 100% Gross Margin 67% Selling, General & Administrative 52% Taxes 0.5% Research & Development 12% Stock-Based Comp & Amortization 11% Adjusted Earnings (Loss)1 1.3% 2007 Actual 100% 65% 66% 0.3% 17% 11% (22.4%) 1 Adjusted Earnings (Loss) excludes S
Slide 11: ev3 is Leading the Way in Endovascular Therapies
21 ev3 is Leading the Way in Endovascular Therapies Improving sales productivity and operational execution Continued improvement in atherectomy product sales Expansion in Neurovascular - Axium leading the way Strong International organization driving penetration and growth Advancing products through
Slide 12: ev3 Investor and Analyst Meeting at TCT
€v3 Investoresa ev3 (NASDAQ: EVV) will host an investor and analyst meeting during the TCT Conference in Washington, D.C. AGENDA: 5:00 to 5:30 pm Cocktail Reception 5:30 to 6:30 pm Management Presentations 6:30 to 7:00 pm Question & Answer Session For those unable to attend the meeting In person, a
Slide 13: Second Quarter of 2008 Highlights
Second Quarter of 2008 Highlights July 28, 2008